Pharmaceutical Industry discussion, review, analysis, news and information.

Raloxifene is a drug commonly used to treat osteoporosis has been recently to be a potential treatment against prostate cancer by researchers at Cedars-Sinai Medical Center .

Since Raloxifene is a drug already on the market, researchers were able to move directly into a Phase II clinical trial. They identified the presence of the beta isoform of the estrogen receptor in prostate cancer tissue samples, then moved directly into studies of animals with human prostate cancer, and then onto human clinical trials. The entire process took only 2-3 years.

This certainly is good news because prostate cancer is the leading cause of cancer and the second leading cause of cancer-related death among men living in the United States.

Source: EurekAlert

Photo Credit: www.drugs-market.com